Volume 20, Number 1Review ArticlesDifferentiating Molecular Risk Assessments for Prostate CancerRisk Assessment ReviewMichael SchulsterMarc A BjurlinBenjamin PressIt is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of “significant” prostate cancer. Herein we discuss these tests and their clinical implications. [Rev Urol. 2018;20(1):12–18 doi: 10.3909/riu0787] © 2018 MedReviews, LLC®Prostate cancerScreeningProstate-specific antigenBiomarkersPSA
Volume 21, Number 1Meeting ReviewsBladder Cancer Academy 2019 Selected SummariesMichael Schulster[Rev Urol. 2019;21(1):23–28] © 2019 MedReviews®, LLC